Simtra BioPharma Solutions, a contract development and manufacturing organization (CDMO) specializing in sterile injectables, has announced a $14 million investment to expand its clinical-scale conjugation and purification capabilities for Antibody-Drug Conjugates (ADCs).
 
Set to be operational by late 2025, this expansion is part of Simtra’s strategy to build a comprehensive end-to-end service offering, from development to clinical and commercial fill/finish, accelerating time to market for its customers.
 
The new clinical suite at Simtra’s Halle/Westfalen, Germany site will support ADC development by offering key capabilities, including:
 

• Conjugation mixing
• Single-use tangential flow filtration
• Diafiltration and buffer exchange

 
The Halle/Westfalen site currently offers clinical and commercial manufacturing services, with expertise in oncology and ADCs. Operating under SafeBridge classification and equipped to handle Category 4 drugs, the site will now provide a more comprehensive range of services for ADC development and manufacturing.
 
Franco Negron, CEO of Simtra, said, “This investment will further strengthen Simtra’s leadership in ADC manufacturing, a growing sector, by extending our capabilities in support of our customers and partners in the value chain.”
 
Lidia Serina, Head of Development Services at Simtra, added, “We are offering customers a true end-to-end solution, from early development to commercial production. This allows for more flexibility, reduces risk, and shortens timelines, ultimately saving our customers time and money.”
 
With this investment, Simtra continues to build on its expertise and infrastructure to serve the evolving needs of the pharmaceutical industry, particularly in the rapidly advancing field of ADCs.
 
This news follows Simtra’s recent announcement of a $250 million expansion of its sterile fill/finish manufacturing campus in Bloomington, Indiana.